In updating the recommendations from the European League against rheumatism (EULAR) in 2018 enabled the new data which are investigated in the last ten years, which emphasizes the role of the patient in treatment and the importance of multimodal therapy.
The emphasis in the recommendations is to optimize and maximize control of symptoms (rather than “protecting joints”). Also, a number of changes in previous recommendations regarding patient education and individualization of treatment.
EULAR recommends nonsteroidal anti-inflammatory drugs (NSAIDs) as first-line drug therapy for patients with osteoarthritis of the hands. Also recommended training in the principles of ergonomics, physical activity, assistive devices, and exercises to improve function and muscle strength as the initial stages of therapy of OA, regardless of the use of NSAIDs.
EULAR recommends the use of disease-modifying Antirheumatic drugs (DMARDs) in the treatment of osteoarthritis of the hands. Also, do not recommend the use of thermotherapy, ultrasound, most intra-articular injection of glucocorticoids, symptomatic slow-acting drugs of osteoartrita and osteotomy.
All the news of the Russian and world medicine in our Telegram channel @MedicineNews.